ATE356875T1 - Gereinigte aktive hcv ns2/3 protease - Google Patents

Gereinigte aktive hcv ns2/3 protease

Info

Publication number
ATE356875T1
ATE356875T1 AT01994573T AT01994573T ATE356875T1 AT E356875 T1 ATE356875 T1 AT E356875T1 AT 01994573 T AT01994573 T AT 01994573T AT 01994573 T AT01994573 T AT 01994573T AT E356875 T1 ATE356875 T1 AT E356875T1
Authority
AT
Austria
Prior art keywords
protease
refolded
chaotropic agent
purified active
inactive
Prior art date
Application number
AT01994573T
Other languages
English (en)
Inventor
Diane Thibeault
Daniel Lamarre
Roger Maurice
Louise Pilote
Arnim Pause
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Application granted granted Critical
Publication of ATE356875T1 publication Critical patent/ATE356875T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT01994573T 2000-12-15 2001-12-13 Gereinigte aktive hcv ns2/3 protease ATE356875T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25603100P 2000-12-15 2000-12-15

Publications (1)

Publication Number Publication Date
ATE356875T1 true ATE356875T1 (de) 2007-04-15

Family

ID=22970839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994573T ATE356875T1 (de) 2000-12-15 2001-12-13 Gereinigte aktive hcv ns2/3 protease

Country Status (13)

Country Link
US (4) US6815159B2 (de)
EP (1) EP1343897B1 (de)
JP (1) JP3878132B2 (de)
AT (1) ATE356875T1 (de)
AU (1) AU2468802A (de)
CA (1) CA2430661C (de)
DE (1) DE60127299T2 (de)
ES (1) ES2282320T3 (de)
HU (1) HUP0302558A3 (de)
IL (2) IL155760A0 (de)
MX (1) MXPA03004835A (de)
NZ (1) NZ526863A (de)
WO (1) WO2002048375A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0006537D0 (en) * 2000-03-17 2000-05-10 Angeletti P Ist Richerche Bio Assays and screening methods
JP3878132B2 (ja) * 2000-12-15 2007-02-07 ベーリンガー インゲルハイム (カナダ) リミテッド 精製活性型hcvns2/3プロテアーゼ
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
US7785875B2 (en) * 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
ES2386462T3 (es) * 2005-10-28 2012-08-21 Boehringer Ingelheim International Gmbh Ensayo de la actividad NS2/3 del virus de la hepatitis C
US20070141701A1 (en) * 2005-12-21 2007-06-21 Boehringer Ingelheim International Gmbh Hepatitis c virus ns2/3 assay
CN116874555B (zh) * 2023-09-08 2023-11-28 成都华任康生物科技有限公司 一种置换液及其试剂盒和相关应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
DE69829381T2 (de) 1997-08-11 2006-04-13 Boehringer Ingelheim (Canada) Ltd., Laval Hepatitis c inhibitor peptide
US6280940B1 (en) 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
CA2383411A1 (en) 1999-08-30 2001-03-08 Paul L. Darke Hepatitis c virus replication inhibitors
GB0006537D0 (en) * 2000-03-17 2000-05-10 Angeletti P Ist Richerche Bio Assays and screening methods
JP3878132B2 (ja) * 2000-12-15 2007-02-07 ベーリンガー インゲルハイム (カナダ) リミテッド 精製活性型hcvns2/3プロテアーゼ

Also Published As

Publication number Publication date
WO2002048375A2 (en) 2002-06-20
US20020192640A1 (en) 2002-12-19
DE60127299T2 (de) 2007-08-30
US20070172936A1 (en) 2007-07-26
JP2004514459A (ja) 2004-05-20
JP3878132B2 (ja) 2007-02-07
AU2468802A (en) 2002-06-24
US6815159B2 (en) 2004-11-09
WO2002048375A3 (en) 2003-02-27
CA2430661A1 (en) 2002-06-20
MXPA03004835A (es) 2005-04-19
US20040077066A1 (en) 2004-04-22
DE60127299D1 (de) 2007-04-26
ES2282320T3 (es) 2007-10-16
EP1343897B1 (de) 2007-03-14
US20070160629A1 (en) 2007-07-12
CA2430661C (en) 2010-10-19
NZ526863A (en) 2006-06-30
EP1343897A2 (de) 2003-09-17
HUP0302558A3 (en) 2012-03-28
IL155760A0 (en) 2003-12-23
US7264811B2 (en) 2007-09-04
HUP0302558A2 (hu) 2003-10-28
IL155760A (en) 2009-02-11

Similar Documents

Publication Publication Date Title
EP1771454A4 (de) Peptidanaloga als hepatitis c-hemmer
PT1268519E (pt) Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
DE60228607D1 (de) Emulsionshaltige zusammensetzngen
DE602004018363D1 (de) Kombinationen für die hcv-behandlung
NO20050009L (no) Blandinger og fremgangsmater for behandling av en undergrunnsformasjon
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
TNSN08033A1 (en) Hcv ns3 protease inhibitors
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DK2004786T3 (da) Rengøringssammensætninger og fremgangsmåder
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
DK1680097T3 (da) Præparater til topisk påföring og fremgangsmåder til afgivelse af et aktivt middel til et substrat
MXPA03006999A (es) Composicion limpiadora espumante suave.
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE60222899D1 (de) Verbindungen, verfahren und zusammensetzungen für die behandlung von infektionen mit dem rinderdiarrhö-virus (bvdv) und dem hepatitis-c-virus (hcv)
DE60127299D1 (de) Gereinigte aktive hcv ns2/3 protease
EP2014676A4 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
UA86775C2 (ru) Способ очистки раствора альфа-1-антитрипсина
ATE378309T1 (de) Verfahren zur reinigung und herstellung von fluorkohlenwasserstoffen
FR2885910A1 (fr) Composition aqueuse de nettoyage pour le traitement du cuivre de semi-conducteurs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1343897

Country of ref document: EP